A new study released Monday said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally ...

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Efforts to find an easy, early COVID-19 treatment may ... can’t emerge because the drug makes too many other damaging mutations,” Denison says. Merck says it can make as many as 10 million ...

Merck (MRK) said Monday it has submitted a formal application to the Food & Drug Administration for emergency approval of its oral COVID treatment. Merck said it's seeking Emergency Use ...

The FDA authorized Merck’s drug for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization, including older people and those with conditions like ...

Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a deal that adds to a surge of industry interest in using so-called bispecific antibodies ...

Drug companies have enlisted generic manufacturers before with $4 and $4, typically after public pressure. For its COVID-19 pill, Merck has set up these partnerships ahead of time, preemptively ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck stock was falling. Rival Summit Therapeutics said its cancer drug Ivonescimab reduced the risk of disease progression ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. Wednesday, the FDA approved Merck ...